+201.0%
GLD vs MRNA
+915.3%
-714.3%
-28.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.2% | -3.4% | +3.6% | +0.2% |
| 7D | -4.6% | -12.1% | +7.5% | -4.3% |
| 30D | -5.5% | -1.3% | -4.2% | -5.5% |
| 3M | -10.9% | +250.9% | -261.8% | -14.1% |
| 6M | -17.4% | +343.0% | -360.5% | -20.7% |
| YTD | -10.3% | +657.4% | -667.8% | -14.2% |
| 1Y | -7.2% | +794.9% | -802.1% | -11.2% |
| 3Y | +96.9% | +218.1% | -121.2% | +88.6% |
| 5Y | +103.8% | -3.4% | +107.1% | +95.3% |
| All | +201.0% | +915.3% | -714.3% | +196.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling